$DVA

DaVita (DVA) anticipates fewer dialysis treatments in Q4 but expects higher revenue per visit to offset the decline. Revenue per treatment may rise from Q3 but remain below Q4 2025 levels. Medicare rate increases are projected at 1.5% to 2%, with a 1% change impacting operating income by $30 million. International business growth is expected to slow after Q3 gains. New dialyzers may improve patient outcomes. DaVita sees growth opportunities in IKC and international markets.

Washington state sued DaVita and Fresenius Medical Care, alleging they suppress competition by requiring nephrologists to sign noncompete agreements, reducing patient treatment options. The state seeks to void these agreements and impose fines. DaVita denies wrongdoing; Fresenius did not comment. The FTC is also investigating. DaVita operates 51 centers in Washington, Fresenius 29, with some areas having only one provider.

DaVita (NYSE:DVA) anticipates growth and drug cost savings to offset 2027 reimbursement pressures. The company expects positive treatment volume growth this year and in 2027, with a net tailwind of about 25 basis points. DaVita is accelerating a nationwide rollout of expanded hemodialysis dialyzers, though financial impact is not expected until late 2028. Technology spending has been a cost headwind, but is expected to slow next year.

Berkshire Hathaway sold $69M of DaVita (DVA) shares, reducing its stake to 28.3M shares. The sale occurred amid HHS kidney care reforms and a securities fraud probe by Pomerantz LLP. DaVita faces regulatory uncertainty and potential competitive pressure from the HHS plan, which aims to expand patient choice and reduce barriers to entry for new dialysis providers. Pomerantz is investigating potential securities fraud claims related to DaVita's disclosures about these risks.

Barclays kept DaVita's rating at Equal-Weight but reduced its price target to $216 from $224, a 3.6% cut. The new target suggests a 15.2% upside from the Oct 30 close of $187.50.

TD Cowen kept its Buy rating on DaVita and increased its price target to $228 from $220, suggesting a 21.6% upside from the Oct 30 close of $187.50.

UBS raised its price target for DaVita (DVA) to $287 from $270, citing improved phosphate binder operating income outlook and cost opportunities. The company expects a 1.5% to 2% Medicare update in 2027. DaVita's Q3 earnings beat estimates, with adjusted EPS of $3.82 and revenue of $3.58B, but shares fell due to cost concerns. The stock trades at a P/E of 15.88, considered undervalued by InvestingPro.

Berkshire Hathaway's shares hit new records in October, with Class A shares peaking at $824,765 and Class B at $550.47. The company gained 8.9% in October, outperforming the S&P 500 and Nasdaq. Berkshire's Alphabet investment lost about a quarter of its value, now worth $29.6 billion. The company also sold $69 million in DaVita shares, maintaining its ownership stake under 45%.

DaVita Inc.'s average price target was reduced from $229 to $227.67 by 6 analysts, with a range of $180 to $270. This implies an 18% upside from the Oct. 29 closing price. The consensus rating remains 'Buy' among 11 analysts.

Nippon Life Insurance bought $6.26M of Corebridge Financial (CRBG) shares at $35.14 each. HF Sinclair (DINO) CEO Franklin Myers acquired $1.11M in shares. XBiotech (XBIT) director John Simard bought $711K in shares. Liberty Energy (LBRT) director Ken Babcock purchased $223K in shares. Berkshire Hathaway sold $69.03M in DaVita (DVA) shares. Talos Energy (TALO) saw a $27.7M share sale by a major owner. Charles Schwab sold $18.1M in SCHWAB (SCHW) shares.